Contrive Datum Insights has published "Rodent Surgery Services Market Size, Share & Industry Analysis, By Type (Pathological Model, Pre-Implanted Model), Application (Research Institutes, Contract Research Organizations, Pharmaceutical/Biopharmaceutical Companies), Animal type (Mice, Rats, Other Rodents), Indication (Oncology, Cardiovascular & Metabolic, Neurological, Other Indications), Service model (Outsourced/Contract Surgical Services, In-House Surgical Services), and Regional Forecast, 2026-2034". The study sizes the global rodent surgery services market at USD 420 million in 2025 and projects growth from USD 459 million in 2026 to USD 942 million by 2034, a compound annual growth rate of 9.4% across the forecast period.
Rodent surgery services cover the surgical creation and preparation of mouse and rat models used in preclinical research, from disease-induction procedures such as tumor implantation and cardiovascular or metabolic surgery to the pre-implantation of telemetry devices, osmotic pumps and vascular or intrathecal cannulas ahead of a study. These procedures are carried out either inside a sponsor's own vivarium or by a specialist contract provider, and are delivered as a live, surgically prepared animal ready for a research protocol rather than as a device or reagent. Buyers are pharmaceutical and biopharmaceutical companies, contract research organizations, and academic or government research institutes commissioning models to support drug discovery, safety and efficacy studies.
Outsourcing of surgical model creation to contract research organizations
Outsourcing of surgical model creation to contract research organizations is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 9.4% a year, the type lines exposed to it move fastest: Pre-Implanted Model compounds at 10.93%, taking its share of revenue from 37% to 42% and its value from USD 155.4 million to USD 395.64 million.
On the upside, the study's bull case assumes the bull case assumes outsourcing penetration accelerates faster than the base case, with contract research capacity expansion in Asia Pacific coming online ahead of schedule and biopharma R&D budgets holding through the forecast period, which would take 2034 revenue to USD 1036.2 million rather than the USD 942 million base case.
However, the bear case assumes a sustained pullback in biopharma R&D spending slows sponsor commissioning of new surgical models, and longer animal welfare review timelines further limit procedure throughput, which would hold 2034 revenue to USD 847.8 million. Pathological Model, which carries 63% of 2025 revenue, already grows at only 8.41% against the market's 9.4%, so the largest part of the base is also its slowest.
Key Players Compete on Pathological Model Volume and Pre-Implanted Model Growth
Competition in the global rodent surgery services market runs along the type axis rather than the regional one. Pathological Model holds 63% of 2025 revenue at USD 264.6 million and remains the largest line through 2034 at 58%, making it the position hardest for a challenger to take. Pre-Implanted Model, growing at 10.93%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 420 million.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | Pathological Model | 63% · USD 264.6 million | — |
| Application | Pharmaceutical/Biopharmaceutical Companies | 44% · USD 184.8 million | Contract Research Organizations 10.61% |
| Animal type | Mice | 58% · USD 243.6 million | Rats 10.34% |
| Indication | Oncology | 34% · USD 142.8 million | — |
| Service model | Outsourced/Contract Surgical Services | 61% · USD 256.2 million | — |
- Based on regional analysis, North America led the global rodent surgery services market in 2025 with 42% of global revenue at USD 176.4 million, reaching USD 348.54 million by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 22% in 2025 to 28% in 2034, with revenue growing from USD 92.4 million to USD 263.76 million.
- Middle East and Africa remains the smallest region throughout, at 4% of 2025 revenue and 4.5% by 2034.
- Pre-Implanted Model is projected to grow at 10.93% over the forecast period, the fastest of any type line.
- The United States is the largest single country market at USD 149.94 million in 2025, 35.7% of global revenue.
The report segments the market across five axes; by type, and by application, animal type, indication and service model; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 847.8 million and USD 1036.2 million by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.